Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
4.660
+0.010 (0.22%)
Dec 20, 2024, 2:10 PM EST - Market open
Journey Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Operating Revenue | 57.77 | 59.66 | 71 | 63.13 | 44.53 | 34.92 |
| Other Revenue | - | 19.52 | 2.67 | - | - | - |
| Revenue | 57.77 | 79.18 | 73.67 | 63.13 | 44.53 | 34.92 |
| Revenue Growth (YoY) | -27.69% | 7.48% | 16.69% | 41.78% | 27.52% | - |
| Cost of Revenue | 24.66 | 26.66 | 30.78 | 25.58 | 14.59 | 10.53 |
| Gross Profit | 33.11 | 52.52 | 42.89 | 37.55 | 29.94 | 24.39 |
| Selling, General & Admin | 39.99 | 43.91 | 59.47 | 39.83 | 22.09 | 19.13 |
| Research & Development | 11.14 | 7.54 | 10.94 | 16.56 | - | - |
| Operating Expenses | 51.13 | 51.45 | 70.41 | 56.39 | 22.09 | 19.13 |
| Operating Income | -18.02 | 1.07 | -27.52 | -18.84 | 7.85 | 5.26 |
| Interest Expense | -1.89 | -1.7 | -2.02 | -7.03 | -0.7 | -0.26 |
| Interest & Investment Income | 0.68 | 0.32 | 0.06 | 0 | - | - |
| Currency Exchange Gain (Loss) | -0.11 | -0.18 | -0.09 | - | - | - |
| Other Non Operating Income (Expenses) | - | - | - | -0.45 | - | - |
| EBT Excluding Unusual Items | -19.34 | -0.49 | -29.57 | -26.32 | 7.15 | 5 |
| Merger & Restructuring Charges | - | - | - | -6.5 | - | - |
| Asset Writedown | - | -3.14 | - | - | - | - |
| Other Unusual Items | 1.13 | - | - | -9.54 | - | - |
| Pretax Income | -18.21 | -3.63 | -29.57 | -42.36 | 7.15 | 5 |
| Income Tax Expense | 0.13 | 0.22 | 0.06 | 1.63 | 1.87 | 1.38 |
| Net Income | -18.34 | -3.85 | -29.63 | -43.99 | 5.28 | 3.63 |
| Net Income to Common | -18.34 | -3.85 | -29.63 | -43.99 | 5.28 | 3.63 |
| Net Income Growth | - | - | - | - | 45.74% | - |
| Shares Outstanding (Basic) | 20 | 18 | 18 | 10 | 9 | 9 |
| Shares Outstanding (Diluted) | 20 | 18 | 18 | 10 | 11 | 10 |
| Shares Change (YoY) | 9.92% | 4.00% | 72.05% | -5.96% | 7.55% | - |
| EPS (Basic) | -0.93 | -0.21 | -1.69 | -4.32 | 0.58 | 0.40 |
| EPS (Diluted) | -0.93 | -0.21 | -1.69 | -4.32 | 0.49 | 0.36 |
| EPS Growth | - | - | - | - | 36.11% | - |
| Free Cash Flow | -27.87 | 5.24 | -13.53 | -2.18 | 5.13 | 6.62 |
| Free Cash Flow Per Share | -1.41 | 0.29 | -0.77 | -0.21 | 0.47 | 0.66 |
| Gross Margin | 57.32% | 66.33% | 58.23% | 59.48% | 67.23% | 69.84% |
| Operating Margin | -31.18% | 1.35% | -37.35% | -29.84% | 17.63% | 15.06% |
| Profit Margin | -31.74% | -4.87% | -40.22% | -69.68% | 11.86% | 10.38% |
| Free Cash Flow Margin | -48.25% | 6.62% | -18.37% | -3.45% | 11.52% | 18.95% |
| EBITDA | -14.76 | 4.84 | -23.24 | -16.37 | 9.28 | 6.44 |
| EBITDA Margin | -25.54% | 6.11% | -31.55% | -25.92% | 20.83% | 18.44% |
| D&A For EBITDA | 3.26 | 3.77 | 4.28 | 2.47 | 1.43 | 1.18 |
| EBIT | -18.02 | 1.07 | -27.52 | -18.84 | 7.85 | 5.26 |
| EBIT Margin | -31.18% | 1.35% | -37.35% | -29.84% | 17.63% | 15.06% |
| Effective Tax Rate | - | - | - | - | 26.14% | 27.56% |
| Revenue as Reported | 57.77 | 79.18 | 73.67 | 63.13 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.